US Patent

US8211889 — Prodrugs of 2,4-pyrimidinediamine compounds and their uses

Composition of Matter · Assigned to Rigel Pharmaceuticals Inc · Expires 2026-01-19 · 0y expired

Vulnerability score 7/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects prodrugs of biologically active 2,4-pyrimidinediamine compounds, including their synthesis and various uses.

USPTO Abstract

The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.

Drugs covered by this patent

Patent Metadata

Patent number
US8211889
Jurisdiction
US
Classification
Composition of Matter
Expires
2026-01-19
Drug substance claim
Yes
Drug product claim
No
Assignee
Rigel Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.